FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 144 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR 5-Year-Old Boy Meets Generous Stem Cell Donor Who Cured Him October 13, 2021 First treatment approved in England for advanced bile duct cancer July 22, 2021 FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma August 14, 2020 Study Advances Fertility Preservation Approach for Male Cancer Survivors April 24, 2019 Load more HOT NEWS El cáncer en mi comunidad: Cómo acceden las personas con cáncer... Mental Health Awareness for Health Care Providers Bringing a Piece of Home to the Hospital Adding Atezolizumab to First-Line Bevacizumab Plus Platinum Regimen Improves Survival in...
